Literature DB >> 17202700

QSAR studies on chalcones and flavonoids as anti-tuberculosis agents using genetic function approximation (GFA) method.

Ponnurengam Malliappan Sivakumar1, Sethu Kailasam Geetha Babu, Doble Mukesh.   

Abstract

Design of compounds having good anti-tubercular activity is gaining much importance in the field of tuberculosis research due to reemergence of antibiotic resistance strains. In this paper quantitative structure activity relationships (QSAR) were developed on chalcones, chalcone-like compounds, flavones and flavanones to understand the relationship between biological activity and structural features. Genetic function approximation (GFA) method was used to identify the descriptors that would lead to good regression equations. The best molecular descriptors identified were Jurs descriptors (Jurs charged partial surface area), hydrogen bond donor, principal moment of inertia, molecular energy, dipole magnetic, molecular area, absorption, distribution, metabolism and excretion (ADME) properties and Chi indices (Kier & Hall chi connectivity indices). Excellent statistically significant models were developed by this approach (r(2)=0.8-0.97) for the four groups of compounds. The cross validated r(2) (XV r(2)) which is an indication of the predictive capability of the model for all the cases was also very good (=0.79-0.94).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202700     DOI: 10.1248/cpb.55.44

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  10 in total

Review 1.  Advances in computationally modeling human oral bioavailability.

Authors:  Junmei Wang; Tingjun Hou
Journal:  Adv Drug Deliv Rev       Date:  2015-01-09       Impact factor: 15.470

Review 2.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.

Authors:  Sean Ekins; Joel S Freundlich; Inhee Choi; Malabika Sarker; Carolyn Talcott
Journal:  Trends Microbiol       Date:  2010-12-02       Impact factor: 17.079

3.  Antimycobacterial potentials of quercetin and rutin against Mycobacterium tuberculosis H37Rv.

Authors:  Kandasamy Sasikumar; Asit Ranjan Ghosh; Azger Dusthackeer
Journal:  3 Biotech       Date:  2018-09-28       Impact factor: 2.406

4.  1-(2-Hy-droxy-4-meth-oxy-phen-yl)-3-(4-methyl-phen-yl)prop-2-en-1-one.

Authors:  G B Thippeswamy; D Vijay Kumar; B S Jayashree; M A Sridhar; J Shashidhara Prasad
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-03-09

5.  (E)-1-(3,4-Dimeth-oxy-phen-yl)-3-[4-(methyl-sulfan-yl)phen-yl]prop-2-en-1-one.

Authors:  Hoong-Kun Fun; Safra Izuani Jama Asik; Prajwal L Lobo; D Jagadeesh Prasad
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-08-27

Review 6.  Molecular targets and anticancer activity of quinoline-chalcone hybrids: literature review.

Authors:  Mamdouh F A Mohamed; Gamal El-Din A Abuo-Rahma
Journal:  RSC Adv       Date:  2020-08-21       Impact factor: 4.036

7.  Crystal structure of (E)-3-(3,4-di-meth-oxy-phen-yl)-1-(1-hy-droxy-naphthalen-2-yl)prop-2-en-1-one.

Authors:  K S Ezhilarasi; D Reuben Jonathan; R Vasanthi; B K Revathi; G Usha
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-04-30

8.  Crystal structures of three 1-[4-(4-bromo-but-oxy)-phen-yl] chalcone derivatives: (E)-1-[4-(4-bromo-but-oxy)-phen-yl]-3-phenyl-prop-2-en-1-one, (E)-1-[4-(4-bromo-but-oxy)-phen-yl]-3-(4-meth-oxy-phen-yl)prop-2-en-1-one and (E)-1-[4-(4-bromo-but-oxy)-phen-yl]-3-(3,4-di-meth-oxy-phen-yl)prop-2-en-1-one.

Authors:  Gunasekaran Maragatham; Sivasamy Selvarani; Perumal Rajakumar; Srinivasakannan Lakshmi
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-07-21

9.  Synthesis of Novel Chalcone-Based Phenothiazine Derivatives as Antioxidant and Anticancer Agents.

Authors:  Nourah A Al Zahrani; Reda M El-Shishtawy; Mahmoud M Elaasser; Abdullah M Asiri
Journal:  Molecules       Date:  2020-10-06       Impact factor: 4.411

10.  Design, synthesis and in silico studies of new quinazolinone derivatives as antitumor PARP-1 inhibitors.

Authors:  Sayed K Ramadan; Eman Z Elrazaz; Khaled A M Abouzid; Abeer M El-Naggar
Journal:  RSC Adv       Date:  2020-08-10       Impact factor: 4.036

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.